TMDX
TransMedics Group Inc
86.40$
-0.3%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2006 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 85.6% | 96.1% | 92.0% | 82.5% | 95.0% | 96.5% | 88.0% | 91.0% | 72.3% | 61.8% | 59.7% | |
| 60.4% | 16.9% | 32.3% | 48.0% | 19.1% | 16.2% | 19.0% | 72.6% | 55.9% | 41.9% | 45.7% | |
| – | 82.3% | 66.7% | 48.0% | 76.6% | 82.6% | 68.5% | 72.6% | 55.9% | 41.9% | 45.7% | |
| – | 2.4% | 2.5% | 8.2% | 6.2% | 4.5% | 4.4% | 10.0% | 9.0% | 12.2% | 7.9% | |
| 5.3% | 10.9% | 21.5% | 22.0% | 10.7% | 7.8% | 11.0% | 7.4% | 6.3% | 5.8% | 4.6% | |
| 10.6% | 3.0% | 6.6% | 8.2% | 4.6% | 3.1% | 11.6% | 8.8% | – | – | – | |
| – | – | – | – | – | – | – | 0.0% | 1.7% | 1.4% | 1.1% | |
| – | – | – | – | – | – | – | – | 0.3% | 0.3% | 0.2% | |
| 40.9% | 33.2% | 556.0% | 111.4% | 48.1% | 31.7% | 49.7% | 32.4% | 80.6% | 71.6% | 55.7% | |
| 23.6% | 16.3% | 29.5% | 29.8% | 15.3% | 7.8% | 17.2% | 8.5% | 7.8% | 7.5% | 8.4% | |
| – | – | 4.9% | – | – | – | 6.4% | 0.5% | 0.3% | 0.3% | 1.2% | |
| 7.0% | 7.3% | 9.5% | 11.2% | 6.9% | 0.8% | 4.9% | 1.2% | 1.8% | 1.3% | 1.0% | |
| 7.5% | 14.5% | 18.5% | 79.9% | 32.4% | 22.8% | 26.1% | 21.2% | 71.7% | 63.3% | 47.0% | |
| 59.1% | 66.8% | -456.0% | -11.4% | 51.9% | 68.3% | 50.3% | 67.6% | 19.4% | 28.4% | 44.3% | |
| -440.4% | -501.4% | -843.7% | -796.9% | -350.9% | -261.9% | -328.0% | -172.7% | -71.3% | -58.2% | -26.0% | |
| – | 24.9% | 39.1% | 45.7% | 13.5% | 16.2% | 20.5% | 10.7% | 4.6% | 4.4% | 3.8% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.